Key Performance
More- Earnings Score: N/A
- Momentum Score: 6
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
OKYO Pharma will present Phase 2 clinical data for urcosimod, its lead candidate for neuropathic corneal pain treatment, at the ASCRS Annual Meeting in Washington, DC on April 11, 2026. The company will also hold a Scientific Advisory Board meeting with leading ophthalmology experts to review data and guide the upcoming Phase 2b/3 trial planned for the first half of 2026. Urcosimod has received FDA Fast Track designation and showed positive efficacy and safety results in the Phase 2 study.
04/07/2026, 7:00 AM • GlobeNewswire
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
OKYO Pharma Limited announced that Chief Development Officer Gary Jacob acquired 30,980 ordinary shares at $1.59 per share. The company is advancing its flagship drug urcosimod, a ChemR23 agonist, following positive Phase 2a data in neuropathic corneal pain patients. OKYO plans to initiate a Phase 2b/3 trial with approximately 150 subjects in the first half of 2026.
03/19/2026, 7:00 AM • GlobeNewswire
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
OKYO Pharma announced that its abstract for urcosimod, a novel non-opioid eye-drop therapy for neuropathic corneal pain (NCP), has been accepted for presentation at the ARVO 2026 Annual Meeting in Denver. The Phase 2a clinical trial demonstrated clinically meaningful pain reduction and quality-of-life improvements in NCP patients, with potential to restore corneal nerve structure. The company plans to initiate a larger Phase 2b/3 trial with approximately 150 patients in the first half of 2026.
02/23/2026, 11:00 AM • GlobeNewswire
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
OKYO Pharma Limited announced a public offering of 10.8 million ordinary shares at $1.85 per share, expected to raise approximately $20 million in gross proceeds (up to $23 million with underwriter option). The company plans to use proceeds for clinical development of its product candidates, including a Phase 2b/3 trial of its flagship drug urcosimod for neuropathic corneal pain. Piper Sandler & Co. is serving as sole manager, with closing expected on February 17, 2026.
02/12/2026, 10:20 PM • GlobeNewswire
OKYO Pharma Announces Public Offering of Ordinary Shares
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company, announced an underwritten public offering of ordinary shares with Piper Sandler & Co. as the sole book-running manager. The company plans to use net proceeds for clinical development of its neuropathic corneal pain and inflammatory eye disease therapies, including a planned Phase 2b/3 trial of its flagship drug urcosimod.
02/12/2026, 4:01 PM • Benzinga
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.